Video

Declan Walsh, MSc, FACP, FRCP, on the Under-Diagnosis of Malnutrition

Declan Walsh, MSc, FACP, FRCP, director, 2014 MASCC/ISOO International Symposium, discusses the under-diagnosis of malnutrition in palliative medicine.

Declan Walsh, MSc, FACP, FRCP, director, 2014 MASCC/ISOO International Symposium, discusses the under-diagnosis of malnutrition in palliative medicine.

This analysis was conducted because there was some concern that many physicians were not recognizing nutrition problems that many patients experience. There was also concern that there was insufficient communication between the medical team and dietician of a patient.

This analysis looked at medical records from dietician and attending physicians regarding nutrition. Researchers learned that the majority of patients were suffering from malnutrition and that, in general, physicians were under-recording the presence of malnutrition. When a physician did identify a nutrition issue, they often came to the same conclusion as a dietician. It is worth noting, Walsh says, that a dietician performs a formal assessment to identify malnutrition, while a physician is dealing with many issues the patient is facing. The information from the dietician and physician is complementary.

<<<

View more from the 2014 MASCC/ISOO Symposium

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School